Can Hyperbaric Oxygen Therapy Help Cancer Treatments Work Better?
Possibly. This 2025 review says early preclinical and clinical studies suggest hyperbaric oxygen therapy can help chemotherapy, radiotherapy, and immunotherapy work better by easing the low-oxygen environment inside tumors. The authors also note open questions about the right dose, long-term safety, and whether HBOT could promote new blood vessel growth in some tumors.
Tumors create low-oxygen zones deep inside them. This low oxygen helps cancer cells resist treatment and spread. HBOT raises the amount of oxygen dissolved in the blood plasma, which can carry oxygen to areas that normal blood flow reaches poorly. This review pulls together preclinical and clinical work on how HBOT might boost standard cancer treatments.
What the Data Show
- Oxygen boost: HBOT substantially increases the oxygen dissolved in plasma
- Radiation: HBOT increases the DNA damage radiation causes in tumor cells
- Drug penetration: HBOT helps anticancer drugs penetrate deeper into tumors
- Immune cells: HBOT eases the immune suppression that low oxygen causes and works together with immune checkpoint drugs
Dr. Kumar’s Take
HBOT attacks the problem from several angles. According to the review, it does not just add oxygen. It also affects oxidative stress, ferroptosis (an iron-dependent form of cell death), blood vessel growth, and the cancer stem cells that help tumors resist treatment.
The review is also clear about what is unsettled. The best pressure and dose are not established, long-term safety needs more study, and HBOT may encourage new blood vessel growth under some conditions. Those questions need answers before HBOT becomes routine. The authors propose adding HBOT to standard cancer regimens; they do not claim it has been proven to improve patient outcomes yet.
HBOT is not a standalone cancer treatment. The idea is to use it as an enhancer alongside chemotherapy, radiation, and immunotherapy. Timing also matters. Some chemotherapy drugs carry extra risks when combined with HBOT.
How HBOT May Enhance Chemotherapy
Tumor centers often have very little oxygen. In general, this low-oxygen environment causes several problems for chemotherapy:
Drug delivery barriers: Drugs often reach only the cells closest to blood vessels. The review lists better drug penetration as one of the effects of HBOT.
Resistance mechanisms: Low oxygen switches on survival proteins such as HIF-1α, which are known to help cancer cells withstand treatment.
Ferroptosis: Ferroptosis is an iron-dependent form of cell death. The review names ferroptosis as one of the pathways HBOT affects.
The review describes HBOT as working against these hallmarks of treatment resistance, based on preclinical and clinical studies.
How HBOT May Enhance Radiotherapy
Radiation therapy creates chemical reactions that damage tumor DNA. These reactions require oxygen to work effectively. Hypoxic (low-oxygen) tumor cells can be 2-3 times more resistant to radiation than well-oxygenated cells.
Raising tumor oxygen levels around the time of radiation is meant to restore that effect. The review reports that HBOT augments the DNA damage caused by radiation.
Separately, HBOT is already an established treatment for some late tissue injuries from radiation, such as radiation cystitis (bladder inflammation).
How HBOT May Enhance Immunotherapy
Modern immunotherapy drugs like PD-1 and CTLA-4 inhibitors have transformed cancer treatment. But they struggle against many solid tumors, partly because a low-oxygen environment suppresses immune cells.
According to the review, HBOT:
- Eases the immune suppression that low oxygen drives
- Works together with immune checkpoint blockade drugs
Important Safety Considerations
HBOT is generally safe when used correctly, but some chemotherapy drugs call for caution when combined with it:
Bleomycin: Risk of lung toxicity.
Doxorubicin: Risk of heart toxicity.
Cisplatin: May impair wound healing.
Higher pressures and longer sessions raise the risk of oxygen toxicity and ear problems. Treatment parameters must be carefully managed.
Practical Takeaways
- Early studies suggest HBOT may enhance chemotherapy, radiotherapy, and immunotherapy, but it should not replace them
- Drug timing matters when combining HBOT with chemotherapy
- The best dose, long-term safety, and effects on tumor blood vessel growth are still open questions
- Always discuss HBOT with your oncologist before pursuing it
Related Studies and Research
FAQs
How does HBOT help chemotherapy drugs penetrate tumors?
Many drugs reach only the cancer cells nearest blood vessels. The review reports that preclinical and clinical studies found HBOT enhances drug penetration into tumors, as part of reversing the low-oxygen conditions that help tumors resist treatment.
Can HBOT be used with any chemotherapy drug?
No. Certain drugs like bleomycin, doxorubicin, and cisplatin carry added risks when combined with HBOT. The timing between these drugs and HBOT matters. Always discuss drug interactions with your oncologist.
What type of cancer responds best to HBOT?
The review covers solid tumors broadly, and the clinical evidence is still early. The rationale applies most to tumors with large low-oxygen regions.
Is HBOT a replacement for standard cancer treatment?
No. HBOT is being studied as an add-on that may enhance other treatments. The authors propose integrating it into combined cancer regimens, not using it alone.
Bottom Line
This 2025 review suggests that hyperbaric oxygen therapy may enhance chemotherapy, radiotherapy, and immunotherapy. By substantially increasing the oxygen dissolved in plasma, HBOT targets tumor hypoxia, a fundamental barrier to effective cancer therapy. Preclinical and clinical studies show it enhances drug penetration, augments radiation-induced DNA damage, eases hypoxia-driven immune suppression, and works together with immune checkpoint drugs. The dose, long-term safety, and possible effects on tumor blood vessel growth remain open questions. HBOT must be carefully timed with certain chemotherapy drugs and used as an add-on to standard treatment, not a replacement.
